All In Biotech

Drug Trial Radar · NCT07344779

A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice

ROAD - Real-World Outcomes of Darolutamide, ADT, With or Without Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,600

Planned (sponsor's estimate)

Start

Jan 29, 2026

Primary completion

Dec 31, 2029

Study completion Jun 30, 2030

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, prospective, open-label, multicenter, multi-cohort, non-interventional observational study designed to describe the real-world effectiveness and safety of darolutamide in combination with androgen deprivation therapy (ADT), with or without docetaxel, in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study aims to enroll approximately 1,600 male patients (800 per cohort) from multiple countries, primarily in Europe, who have a diagnosis of mHSPC and for whom a decision to treat with darolutamide has been made by the treating physician prior to enrollment. The primary objective is to estimate the proportion of patients achieving undetectable prostate-specific antigen (PSA) levels (\<0.2 ng/mL) at 1 year of treatment in each cohort. Secondary objectives include describing patient demographics, clinical characteristics, prior and concomitant treatments, adverse events, and clinical effectiveness measures such as overall survival, time to new treatment, time to castration resistance, and time to PSA progression. Further objectives involve assessing quality of life, reasons for not adding docetaxel, outcomes by patient subgroups (e.g., Gleason score, disease volume, ECOG status), genomic testing results, and hospitalization rates. Data will be collected using electronic case report forms (eCRF) during routine clinical practice, with no additional diagnostic or monitoring procedures required beyond standard care. All patients must provide informed consent prior to participation. The study will comply with applicable regulatory requirements, including IEC/IRB approval in all participating countries. Statistical analyses will be descriptive and exploratory, with interim analyses planned after 200, 400, and 600 patients per cohort have completed at least 12 months of treatment or discontinued therapy. The study is expected to provide valuable insights into the real-world use of darolutamide in mHSPC, supporting clinical decision-making and enhancing understanding of treatment patterns, effectiveness, and safety in diverse patient populations.

Conditions

  • Metastatic Hormone-Sensitive Prostate Cancer

Interventions

  • Darolutamide (BAY 1841788)Drug

    Darolutamide administered per local standard of care in combination with ADT.

  • ADTDrug

    Androgen deprivation therapy administered per local standard of care.

  • DocetaxelDrug

    Docetaxel administered per local standard of care in combination with darolutamide and ADT for cohort 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients in cohort 1 achieving undetectable PSA (<0.2 ng/mL) at 1 yearTime frame: after 1 year of treatment
  2. Proportion of patients in cohort 2 achieving undetectable PSA (<0.2 ng/mL) at 1 yearTime frame: after 1 year of treatment

Locations

16 sites in 16 countries. Site status is shown where the registry gives one.

  • Many Locations

    Many Locations, Belgium · Recruiting

  • Many Locations

    Many Locations, Finland · Recruiting

  • Many Locations

    Many Locations, France · Recruiting

  • Many Locations

    Many Locations, Germany · Not yet recruiting

  • Many Locations

    Many Locations, Greece · Recruiting

  • Many Locations

    Many Locations, Israel · Recruiting

  • Many Locations

    Many Locations, Italy · Recruiting

  • Many Locations

    Many Locations, Lithuania · Not yet recruiting

  • Many Locations

    Many Locations, Norway · Not yet recruiting

  • Many Locations

    Many Locations, Poland · Recruiting

  • Many Locations

    Many Locations, Portugal · Not yet recruiting

  • Many Locations

    Many Locations, Saudi Arabia · Not yet recruiting

  • Many Locations

    Many Locations, Spain · Recruiting

  • Many Locations

    Many Locations, Sweden · Not yet recruiting

  • Many Locations

    Many Locations, Switzerland · Recruiting

  • Many Locations

    Many Locations, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.